228 related articles for article (PubMed ID: 9794097)
1. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
Paolisso G; Tagliamonte MR; Rizzo MR; Gualdiero P; Saccomanno F; Gambardella A; Giugliano D; D'Onofrio F; Howard BV
Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
[TBL] [Abstract][Full Text] [Related]
2. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
[TBL] [Abstract][Full Text] [Related]
4. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
[TBL] [Abstract][Full Text] [Related]
5. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
Saloranta C; Taskinen MR; Widen E; Härkönen M; Melander A; Groop L
Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
[TBL] [Abstract][Full Text] [Related]
7. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
8. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
Cusi K; Kashyap S; Gastaldelli A; Bajaj M; Cersosimo E
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1775-81. PubMed ID: 17299078
[TBL] [Abstract][Full Text] [Related]
9. The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
Berrish TS; Elliott C; Cooper BG; Reed JW; Orskov H; Alberti KG; Walker M
Diabet Med; 1993 Mar; 10(2):152-8. PubMed ID: 8458192
[TBL] [Abstract][Full Text] [Related]
10. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
Bajaj M; Suraamornkul S; Kashyap S; Cusi K; Mandarino L; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM.
Puhakainen I; Yki-Järvinen H
Diabetes; 1993 Dec; 42(12):1694-9. PubMed ID: 8243814
[TBL] [Abstract][Full Text] [Related]
12. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
[TBL] [Abstract][Full Text] [Related]
13. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
Alvarez P; Isidro L; Peinó R; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2003 Oct; 59(4):431-6. PubMed ID: 14510904
[TBL] [Abstract][Full Text] [Related]
14. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Fulcher GR; Walker M; Farrer M; Johnson AS; Alberti KG
Metabolism; 1993 Mar; 42(3):308-14. PubMed ID: 8487648
[TBL] [Abstract][Full Text] [Related]
15. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
[TBL] [Abstract][Full Text] [Related]
16. Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects.
Qvigstad E; Mostad IL; Bjerve KS; Grill VE
Am J Physiol Endocrinol Metab; 2003 Jan; 284(1):E129-37. PubMed ID: 12485810
[TBL] [Abstract][Full Text] [Related]
17. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
[TBL] [Abstract][Full Text] [Related]
18. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
Merovci A; Abdul-Ghani M; Mari A; Solis-Herrera C; Xiong J; Daniele G; Tripathy D; DeFronzo RA
J Clin Endocrinol Metab; 2016 Mar; 101(3):1249-56. PubMed ID: 26765576
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of ghrelin on insulin secretion and glucose disposal rate in gastrectomized patients.
Damjanovic SS; Lalic NM; Pesko PM; Petakov MS; Jotic A; Miljic D; Lalic KS; Lukic L; Djurovic M; Djukic VB
J Clin Endocrinol Metab; 2006 Jul; 91(7):2574-81. PubMed ID: 16621911
[TBL] [Abstract][Full Text] [Related]
20. Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox.
Fulcher GR; Walker M; Catalano C; Farrer M; Alberti KG
Clin Sci (Lond); 1992 May; 82(5):565-71. PubMed ID: 1317767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
